Mitoxantrone permeability in MDCKII cells is influenced by active influx transport

Molecular Pharmaceutics

Volumn 4, Issue 3, 2007, Pages 475-483

  Pan, Guoyu ^a   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

bcrp1; Efflux transporter; Influx transporter; MDCKII cell; Mitoxantrone

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; BREAST CANCER RESISTANCE PROTEIN 1; MITOXANTRONE; PROBENECID; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; ANIMAL CELL; APICAL MEMBRANE; ARTICLE; CELL TYPE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TRANSPORT; EFFUSION; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CELL MEMBRANE PERMEABILITY; DOGS; DRUG RESISTANCE, NEOPLASM; MITOXANTRONE; PROBENECID; RECOMBINANT PROTEINS; TETRAETHYLAMMONIUM; TRANSFECTION;

EID: 34250887484     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp060083b     Document Type: Article

References (30)

1. Greidanus, J.; de Vries, E. G.; Mulder, N. H.; Sleijfer, D. T.; Uges, D. R.; Oosterhuis, B.; Willemse, P. H. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J. Clin. Oncol. 1989, 7, 790-7.
2. Hagemeister, F.; Cabanillas, F.; Coleman, M.; Gregory, S. A.; Zinzani, P. L. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist 2005, 10, 150-9.
3. Neuhaus, O.; Kieseier, B. C.; Hartung, H. P. Mechanisms of mitoxantrone in multiple sclerosis - what is known? J. Neurol. Sci. 2004, 223, 25-7.
4. Xu, D.; Arestrom, I.; Virtala, R.; Pisa, P.; Peterson, C.; Gruber, A. High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone. Br. J. Haematol. 1999, 106, 627-33.
5. Wells, R. J.; Odom, L. F.; Gold, S. H.; Feusner, J.; Krill, C. E.; Waldron, P.; Moulton, T. A.; Knoppell, E.; White, M. L.; Cairo, M. S. Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. Med. Pediatr. Oncol. 1994, 22, 244-9.
6. Hazlehurst, L. A.; Gros, P.; Dalton, W. S. Chromosome mediated gene transfer of drug resistance to mitoxantrone. Anticancer Res. 1998, 18, 1005-10.
7. Morrow, C. S.; Peklak-Scott, C.; Bishwokarma, B.; Kute, T. E.; Smitherman, P. K.; Townsend, A. J. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol. Pharmacol. 2006, 69, 1499-505.
8. Hazlehurst, L. A.; Foley, N. E.; Gleason-Guzman, M. C.; Hacker, M. P.; Cress, A. E.; Greenberger, L. W.; De, Jong, M. C.; Dalton, W. S. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res. 1999, 59, 1021-8.
9. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA. 1998, 95, 15665-70.
10. Dai, H.; Marbach, P.; Lemaire, M.; Hayes, M.; Elmquist, W. F. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J. Pharmacol. Exp. Ther. 2003, 304, 1085-92.
11. Ito, K.; Suzuki, H.; Horie, T.; Sugiyama, Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 2005, 22, 1559-77.
12. Kim R. B. Transporters and xenobiotic disposition. Toxicology 2002, 181-2, 291-7.
13. Thomas, J.; Wang, L.; Clark, R. E.; Pirmohamed, M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104, 3739-45.
14. Canal, P.; Attal, M.; Chatelut, E.; Guichard, S.; Huguet, F.; Muller, C.; Schlaifer, D.; Laurent, G.; Houin, G.; Bugat, R. Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Res. 1993, 53, 4850-4.
15. Allen, J. D.; Brinkhuis, R. F.; Wijnholds, J.; Schinkel, A. H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 1999, 59, 4237-41.
16. Jang, S. H.; Wientjes, M. G.; Au, J. L. Interdependent effect of P-glycoprotein-mediated drug efflux and intracellular drug binding on intracellular paclitaxel pharmacokinetics: application of computational modeling. J. Pharmacol. Exp. Then 2003, 304, 773-80.
17. Jang, S. H.; Wientjes, M. G.; Au, J. L. Kinetics of P-glycoprotein- mediated efflux of paclitaxel. J. Pharmacol. Exp. Ther. 2001, 298, 1236-42.
18. Jones, K.; Hoggard, P. G.; Sales, S. D.; Khoo, S.; Davey, R.; Back, D. J. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001, 15, 675-81.
19. Kager, L.; Cheok, M.; Yang, W.; Zaza, G.; Cheng, Q.; Panetta, J. C.; Pui, C. H.; Downing, J. R.; Relling, M. V.; Evans, W. E. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J. Clin. Invest. 2005, 115, 110-7.
20. Crossman L. C.; Druker, B. J.; Deininger, M. W. N. hOCT 1 and resistance to imatinib. Blood 2005, 106, 1133-4.
21. Pirmohamed, M.; Wang, L.; Clark, R. E. Imatinib and hOCT1: implications for drug resistance and interactions. Blood 2005, 106, 1134.
22. Koepsell, H.; Endou, H. The SLC22 drug transporter family. Pfluegers Arch. 2004, 447, 666-76.
23. Goh, L. B.; Spears, K. J.; Yao, D.; Ayrton, A.; Morgan, P.; Roland, Wolf, C.; Friedberg, T. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem. Pharmacol. 2002, 64, 1569-78.
24. Raghunand, N.; Mahoney, B.; van, Sluis, R.; Baggett, B.; Gillies, R. J. Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone. Neoplasia 2001, 3, 227-35.
25. Ciarimboli, G.; Schlatter, E. Regulation of organic cation transport. Pfluegers Arch. 2005, 449, 423-41.
26. Shu, Y.; Bello, C. L.; Mangravite, L. M.; Feng, B.; Giacomini, K. M. Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J. Pharmacol. Exp. Ther. 2001, 299, 392-8.
27. Tamai, I.; Yabuuchi, H.; Nezu, J.; Sai, Y.; Oku, A.; Shimane, M.; Tsuji, A. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett. 1997, 419, 107-11.
28. Enomoto, A.; Wempe, MF.; Tsuchida, H.; Shin, H. J.; Cha, S. H.; Anzai, N.; Goto, A.; Sakamoto, A.; Niwa, T.; Kanai, Y.; Anders, M. W.; Endou, H. Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J. Biol. Chem. 2002, 277, 36262-71.
29. Ohashi, R.; Tamai, I.; Inano, A.; Katsura, M.; Sai, Y.; Nezu, J.; Tsuji, A. Studies on functional sites of organic cation/carnitine transporter OCTN2 (SLC22A5) using a Ser467Cys mutant protein. J. Pharmacol. Exp. Ther. 2002, 302, 1286-94.
30. Xiao, Y.; Davidson, R.; Smith, A.; Pereira, D.; Zhao, S.; Soglia, J.; Gebhard, D.; de Morais, S.; Duignan, D. B. A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol. Pharmacol. 2006, 3, 45-54.